

A randomised controlled trial evaluating the effectiveness of heliox in post-extubation stridor

Submission date	Recruitment status	<input type="checkbox"/> Prospectively registered
12/09/2003	No longer recruiting	<input type="checkbox"/> Protocol
Registration date	Overall study status	<input type="checkbox"/> Statistical analysis plan
12/09/2003	Completed	<input type="checkbox"/> Results
Last Edited	Condition category	<input type="checkbox"/> Individual participant data
16/03/2016	Surgery	<input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr James Austin

Contact details

PICU
St Mary's Hospital
Praed Street
London
United Kingdom
W2 1NY
+44 (0)20 7886 6666
drjamesaustin@hotmail.com

Additional identifiers

Protocol serial number

N0241121241

Study information

Scientific Title

A randomised controlled trial evaluating the effectiveness of heliox in post-extubation stridor

Study objectives

Does heliox have a role to play in the immediate management of post-extubation stridor, in reducing adrenaline requirement and need for re-intubation?

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Intubation

Interventions

Patients will be extubated initially into 30% FiO₂, and their SpO₂ recorded when stable for scoring purposes. Higher or lower FiO₂ can then be given if needed. Patients will be entered into the study if they have any stridor at all (ie modified Syracuse score 1 or more) between 5 min and 24 h post extubation. This will be assessed by a doctor who is prepared to immediately randomise, and to start heliox if indicated. If stridor develops earlier than 5 min it should be observed if still present at 5 min then proceed with randomisation. As soon as a patient becomes eligible, he/she will be randomised by coin toss: HEads for HElixo , tails to simply continue on required FiO₂. Patients randomised to heliox will commence this immediately.

The modified Syracuse score (DEVELOPED FOR THIS STUDY BUT BASED ON A VALIDATED SCORE - see below for details) will be scored:

1. At 5 minutes post-extubation;
2. At the moment that stridor is first recognised;
3. One minute after randomisation;
4. Every thirty minutes after randomisation, until the trial ends; and
5. At the end of any dose of nebulised adrenaline

Any patient with a modified Syracuse score of 3 or more at points 3, 4 or 5 will receive nebulised adrenaline 1:1000 0.5ml/kg (maximum single dose 5ml). If the score remains 3 or more at the completion of a nebuliser, the dose will be immediately repeated; if not, no further dose will be given until the next score (30 minutes after the last, pre-nebuliser score). A modified Syracuse score of 3 or more persisting after three continuous adrenaline nebulisers will be an indication for re-intubation.

Once started, heliox may be stopped if the modified Syracuse score is 0 on three successive occasions (i.e. for one hour). A further two scores should be obtained thereafter: if stridor returns within one hour off heliox, it may be recommenced.

A patient's involvement in the trial will be ended on any of the following:

1. the parent demands withdrawal from the study
2. the clinician feels that the study is compromising patient care
3. the patient is re-intubated
4. the patient is free of stridor for one hour, not being on heliox.

If a patient exits the trial and subsequently develops stridor again (within 24 hours of extubation), he/she may be re-entered and re-randomised. Thus one patient may enter the trial more than once, potentially in different treatment arms, if he/she has more than one episode of stridor separated by at least one hour.

Pre-extubation dexamethasone is neither encouraged nor discouraged by this trial, but should be recorded in either event. The avoidance of steroids would probably increase the numbers of patients eligible for the study; however, it would not be ethical to deny the patient this treatment if the clinician felt it was clinically indicated.

Intervention Type

Procedure/Surgery

Phase

Not Specified

Primary outcome(s)

1. Stridor scores analysed by Student's t-test
2. Adrenaline use (directly linked to stridor scores) analysed by Student's t-test
3. Re-intubation rates analysed by Chi-squared test

Key secondary outcome(s)

Not provided at time of registration

Completion date

31/08/2003

Eligibility

Key inclusion criteria

All children intubated are eligible for the trial. Parents will be approached and consented at the appropriate time (prior to planned extubation).

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Child

Sex

All

Key exclusion criteria

Patients with undrained pneumothoraces or intracranial air will be excluded.

Date of first enrolment

27/03/2003

Date of final enrolment

31/08/2003

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

PICU

London

United Kingdom

W2 1NY

Sponsor information

Organisation

Department of Health (UK)

Funder(s)

Funder type

Hospital/treatment centre

Funder Name

St Mary's NHS Trust (UK)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration